Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 285.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 394,489 shares of the medical research company’s stock after buying an additional 292,137 shares during the quarter. Fisher Asset Management LLC owned approximately 0.07% of Amgen worth $102,820,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Conservest Capital Advisors Inc. increased its position in Amgen by 20.6% during the 4th quarter. Conservest Capital Advisors Inc. now owns 1,026 shares of the medical research company’s stock worth $267,000 after purchasing an additional 175 shares in the last quarter. SVB Wealth LLC purchased a new stake in Amgen in the 4th quarter valued at about $6,747,000. Tower Bridge Advisors grew its holdings in Amgen by 2.1% in the 4th quarter. Tower Bridge Advisors now owns 13,479 shares of the medical research company’s stock valued at $3,513,000 after buying an additional 280 shares during the period. Fortress Financial Group LLC purchased a new stake in shares of Amgen during the 4th quarter worth about $758,000. Finally, Private Trust Co. NA grew its holdings in shares of Amgen by 6.0% during the 4th quarter. Private Trust Co. NA now owns 9,955 shares of the medical research company’s stock worth $2,595,000 after purchasing an additional 560 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a report on Wednesday, February 5th. Bank of America boosted their target price on Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a report on Thursday, February 6th. Redburn Partners decreased their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Truist Financial decreased their target price on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Finally, Citigroup reiterated a “neutral” rating on shares of Amgen in a report on Wednesday, February 5th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amgen has an average rating of “Hold” and an average price target of $314.09.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $308.06 on Friday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The company has a market capitalization of $165.49 billion, a price-to-earnings ratio of 40.80, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56. The business has a 50 day simple moving average of $280.87 and a 200-day simple moving average of $299.99.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.09%. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is 126.09%.

Insider Activity

In related news, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at $8,496,669.44. This represents a 46.35 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David M. Reese sold 8,711 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the transaction, the executive vice president now owns 62,147 shares of the company’s stock, valued at approximately $18,222,743.34. The trade was a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.